Detalles de la búsqueda
1.
Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response.
Hum Genomics
; 17(1): 37, 2023 04 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37098643
2.
A Nationwide Study of the Delayed Diagnosis and the Clinical Manifestations of Predominantly Antibody Deficiencies and CTLA4-Mediated Immune Dysregulation Syndrome in Greece.
Medicina (Kaunas)
; 60(5)2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38792965
3.
Predisposing factors for advanced liver fibrosis in patients with sickle cell disease.
Br J Haematol
; 202(6): 1192-1198, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37438880
4.
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.
Br J Haematol
; 192(6): 978-987, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32862447
5.
TACI Mutations in Primary Antibody Deficiencies: A Nationwide Study in Greece.
Medicina (Kaunas)
; 57(8)2021 Aug 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34441032
6.
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
Hematol Oncol
; 38(4): 541-553, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32495951
7.
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.
Int J Cancer
; 145(2): 559-568, 2019 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30650184
8.
Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Ann Hematol
; 98(6): 1383-1392, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30877373
9.
National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality.
Ann Hematol
; 98(1): 55-66, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30196444
10.
Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in ß-Thalassemia Intermedia: A Validation Cohort Study.
Hemoglobin
; 43(1): 27-33, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31039620
11.
Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in ß-type hemoglobinopathy patients.
Hum Genomics
; 11(1): 24, 2017 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29061162
12.
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms.
Am J Hematol
; 98(5): E119-E122, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36808739
13.
Treatment of chronic hepatitis C with direct-acting antivirals in patients with ß-thalassaemia major and advanced liver disease.
Br J Haematol
; 178(1): 130-136, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28439915
14.
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
Am J Hematol
; 92(5): 420-428, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28142202
15.
Rare lobular capillary hemangioma associated with azacitidine in high-risk myelodysplastic syndrome patient.
Dermatol Ther
; 34(2): e14884, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33594760
16.
Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMML.
Clin Epigenetics
; 16(1): 79, 2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38879530
17.
A Cross-Sectional, Multicentric, Disease-Specific, Health-Related Quality of Life Study in Greek Transfusion Dependent Thalassemia Patients.
Healthcare (Basel)
; 12(5)2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38470634
18.
Hepatitis C in patients with ß-thalassemia major. A single-centre experience.
Ann Hematol
; 92(6): 739-46, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23412560
19.
Real-world complication burden and disease management paradigms in transfusion-related ß-thalassaemia in Greece: Results from ULYSSES, an epidemiological, multicentre, retrospective cross-sectional study.
EJHaem
; 4(3): 569-581, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37601860
20.
Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data.
Front Med (Lausanne)
; 10: 1226114, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37901415